Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
ME

NASDAQ · MESO

Mesoblast Limited

Healthcare · Biotechnology

$13.61

Down-$0.61 (-4.29%)

Updated Oct 7, 2026, 3:21 AM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.36B
P/E ratio
-27.76
Dividend yield
0.00%
52-week range
$13.05 – $21.50
Volume
404.7K
Avg. volume
231.33K

Price performance · MESO

MESO price history

1M range · 0 trading sessions · Daily adjusted prices

MESO does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest MESO news

The latest Smart Investors Daily articles mentioning MESO.

Stock researchCompany · Overview

MESO research

Overview

Company profile and research snapshot.

Company profile

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$11.50
Implied upside
—
Analysts
—
MESO recent ratings
DateFirmRatingTarget
Sep 22, 2026BELL POTTER SECURITIESBuy—
Sep 5, 2026CANACCORD GENUITYBuy—
Sep 3, 2026MAXIM GROUPBuy—
Sep 2, 2026JEFFERIESBuy—
Aug 28, 2026CANTOR FITZGERALDOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 1, 2026

Cochlear And 2 Australian Healthcare Stocks To Watch

Australian inflation accelerated to 4% in August, and interest rates now sit at a 15 year high of 4.6%. That mix is putting cost pressure on households while lifting the appeal of resilient sectors. Healthcare often holds up when budgets tighten because treatment is hard to postpone. This article walks through three leading Australian healthcare stocks from a high quality screener that targets robust balance sheets and proven business models. The three stocks in focus below are a starting...

Yahoo · Sep 29, 2026

3 Australian Founder Led Stocks With Revenue Growth Up To 37%

With Australian interest rates now at a 15-year high, cheap debt no longer does the heavy lifting for corporate performance. Investors are paying closer attention to who is actually steering each business. Founder led Australian companies, where the original builders still call key shots, can look appealing when capital is more expensive and decisions carry extra weight. This article highlights three such stocks from our founder focused screener. These three founder led Australian stocks are...

Yahoo · Sep 27, 2026

3 Australian Growth Stocks With Earnings Growth Up To 65%

Bond yields at two decade highs have reset borrowing costs across the globe, which puts pressure on heavily indebted businesses but shines a spotlight on Australian companies that can fund their own expansion. When insiders own meaningful stakes in fast growing outfits, incentives to grow carefully rather than chase cheap debt can be stronger. This article walks through three high growth, high insider ownership stocks from that group. The three stocks below are a small sample, and the full...

Yahoo · Sep 25, 2026

Elite Australian Owner Operator Stocks To Own In September 2026

Global bond yields are climbing, and central banks are tightening policy to keep inflation in check. That raises the bar for every listed company. Founder led Australian businesses can be different because leaders often have more of their own wealth and reputation on the line when conditions get tougher. This article highlights three stocks from our founder focused screener that explore how owner minded leadership may influence long term value creation. These three founder led stocks are just...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By